United Therapeutics Corporation
587.50USD
+2.7100 (+0.46%)
Fetching financial statements from SEC filings…
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on UTHR.
| In $M except per-share | Q2 FY26 | Q1 FY26 | Q4 FY25* | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24* | Q3 FY24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 783 | 782 | 790 | 800 | 799 | 794 | 736 | 749 |
| Cost of Revenue | 100 | 133 | 103 | 101 | 88 | 93 | 76 | 83 |
| Gross Profit | 684 | 648 | 687 | 699 | 711 | 702 | 660 | 666 |
| Operating Income | 331 | 326 | 357 | 389 | 365 | 383 | 358 | 343 |
| Net Income | 333 | 275 | 364 | 339 | 310 | 322 | 301 | 309 |
| EPS (Diluted) | $7.27 | $5.82 | $7.69 | $7.16 | $6.41 | $6.63 | $6.21 | $6.39 |
* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)